Sharma Aseem, Majid Imran, Kumar Hari K, Banodkar Pravin, Mhatre Madhulika, Mohod Bhagyashree, Jaiswal Ashok
Department of Dermatology, Skin Saga Centre for Dermatology, Mumbai, IND.
Department of Dermatology, Cutis Institute of Dermatology, Srinagar, IND.
Cureus. 2023 Jul 5;15(7):e41418. doi: 10.7759/cureus.41418. eCollection 2023 Jul.
Background Vitiligo, a chronic autoimmune depigmenting skin disease, affects a significant portion of the global population. One of the topical treatment options for vitiligo is basic fibroblast growth factor (bFGF)-related decapeptide (bFGFrP) 0.1% solution. This study aimed to assess the real-world effectiveness and safety of decapeptide in treating vitiligo. Methods This retrospective analysis utilized data collected from routine clinical practice in the management of vitiligo, focusing on patients treated with topical decapeptide lotion (Melgain™, manufactured by Zydus Healthcare Ltd., Ahmedabad, India). The primary outcome measures included the extent of re-pigmentation (EOR) and the grade of re-pigmentation (GOR) assessed at each follow-up visit. Results The analysis included data from 65 patients (24 males and 41 females) with an average age of 30.83 years. Segmental vitiligo was present in 52.31% of cases, with the face being the most commonly affected site. Among the patients, 33 received decapeptide as monotherapy, while 32 received decapeptide alongside adjuvant drug/phototherapy. The mean duration of treatment was five months. The first, second, and final follow-ups were observed to be at a mean of 45 days, two months, and five months, respectively. During the second and final follow-up, a significant response (>75% re-pigmentation) was observed in 12% (eight) and 71% (46) of the patients. A mild response (<50% re-pigmentation) was noted in 45% (29) of the patients during the first follow-up visit, 15% (10) during the second follow-up visit, and 6% (four) during the final follow-up visit. Grade 6 and 7 re-pigmentation occurred in a higher number of patients at the final visit, indicating treatment effectiveness. Overall, nearly all patients (96.92%) reported excellent tolerability of the decapeptide lotion based on the global assessment of tolerability. Conclusion This real-world study demonstrates that decapeptide promotes re-pigmentation and improves patient outcomes in vitiligo. Both decapeptide regimens, as monotherapy or in combination with other therapies, were effective and well tolerated by most patients. Thus, decapeptide represents a safe and effective therapeutic option for vitiligo treatment.
白癜风是一种慢性自身免疫性色素脱失性皮肤病，影响着全球相当一部分人口。白癜风的局部治疗选择之一是碱性成纤维细胞生长因子（bFGF）相关十肽（bFGFrP）0.1%溶液。本研究旨在评估十肽治疗白癜风的真实疗效和安全性。方法：本回顾性分析利用了白癜风管理常规临床实践中收集的数据，重点关注接受外用十肽洗剂（Melgain™，由印度艾哈迈达巴德的Zydus Healthcare Ltd.生产）治疗的患者。主要结局指标包括每次随访时评估的色素再沉着程度（EOR）和色素再沉着等级（GOR）。结果：分析纳入了65例患者（24例男性和41例女性）的数据，平均年龄为30.83岁。节段性白癜风占病例的52.31%，面部是最常受累部位。其中，33例患者接受十肽单药治疗，32例患者接受十肽联合辅助药物/光疗。平均治疗持续时间为五个月。首次、第二次和末次随访的平均时间分别为45天、两个月和五个月。在第二次和末次随访期间，分别有12%（8例）和71%（46例）的患者出现显著反应（色素再沉着>75%）。在首次随访时，45%（29例）的患者出现轻度反应（色素再沉着<50%），第二次随访时为15%（10例），末次随访时为6%（4例）。末次随访时，更多患者出现6级和7级色素再沉着，表明治疗有效。总体而言，根据耐受性的整体评估，几乎所有患者（96.92%）报告十肽洗剂耐受性良好。结论：这项真实世界研究表明，十肽可促进白癜风患者的色素再沉着并改善患者结局。十肽单药治疗方案或与其他疗法联合使用均有效，且大多数患者耐受性良好。因此，十肽是白癜风治疗的一种安全有效的治疗选择。
